CSPC Pharmaceutical Group Secures Drug Registration Approval for Lansoprazole Enteric-Coated Capsules
Key Highlights:
- Drug Registration Approval: CSPC Pharmaceutical Group Limited (“the Company”, Stock Code: 1093) has announced that its Lansoprazole Enteric-coated Capsules (30mg) have been granted drug registration approval by the National Medical Products Administration (NMPA) of the People’s Republic of China.
- Product Details: Lansoprazole is a well-established proton pump inhibitor (PPI) designed to inhibit gastric acid secretion. It is clinically indicated for several gastrointestinal conditions, including gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, and anastomotic ulcer.
- Clinical Mechanism: Once the product reaches the acid-secreting canaliculi of the gastric mucosal parietal cells, it is converted into its active form under acidic conditions. This active compound irreversibly binds to the sulfhydryl (-SH) groups of the proton pump (H+/K+-ATPase), inhibiting the enzyme’s activity and effectively suppressing gastric acid secretion.
- Market Impact: The approval of this product further broadens CSPC’s portfolio in the high-growth field of digestion and metabolism, reinforcing its presence in one of the most commonly prescribed drug segments in clinical practice.
Implications for Shareholders and Investors
- Potential Share Price Catalyst: The successful approval and anticipated launch of Lansoprazole Enteric-coated Capsules can be viewed as a price-sensitive development. It signals the company’s capability to innovate and expand its product range, potentially driving future revenue growth within the competitive Chinese pharmaceutical market.
- Strategic Portfolio Expansion: By enhancing its offerings in digestion and metabolism therapeutics—a large and recurrent prescription market—CSPC is positioned to capture greater market share, which could positively impact the Company’s financial performance and valuation.
- Regulatory Milestone: Obtaining NMPA approval indicates that the product meets rigorous safety and efficacy standards, which should boost investor confidence in the Company’s R&D and regulatory compliance capabilities.
Board and Management Update
The announcement was made by Mr. Cai Dong Chen, Chairman of the Board, on 26 May 2026. The Board consists of a robust leadership team, including multiple executive and independent non-executive directors, underscoring strong corporate governance and strategic guidance.
Conclusion
The NMPA’s approval of CSPC’s Lansoprazole Enteric-coated Capsules is a significant milestone that may influence the Company’s share price and future growth trajectory. Investors should closely monitor further updates regarding the product’s commercialization and market uptake.
Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own due diligence and consult professional financial advisors before making any investment decisions.
石藥集團蘭索拉唑腸溶膠囊獲國家藥品監督管理局批准註冊
重點摘要：
- 藥品註冊批文： 石藥集團有限公司（「公司」，股份代號：1093）宣布，其研發的蘭索拉唑腸溶膠囊（30mg）已獲中華人民共和國國家藥品監督管理局批准註冊。
- 產品詳情： 蘭索拉唑是一種成熟的質子泵抑制劑（PPI），主要用於抑制胃酸分泤。臨床適應症包括胃潰瘍、十二指腸潰瘍、反流性食管炎、卓-艾氏症候群以及吻合口潰瘍。
- 臨床機理： 藥物到達胃黏膜壁細胞的分泌小管後，在酸性環境下轉化為活性物質，並與區域內質子泵（H+/K+-ATP酶）的巰基（-SH）結合，從而抑制酶活性，有效抑制胃酸分泤。
- 市場影響： 此產品的批准進一步豐富集團在消化及代謝領域的產品組合，強化在臨床常用藥物市場的佔有率。
對股東及投資者的重要影響
- 潛在股價催化劑： 產品獲批及預計上市屬於敏感消息，有望推動公司於中國醫藥市場的收入增長，對股價構成正面影響。
- 戰略產品組合擴展： 集團加強消化及代謝藥物領域的布局，有利於搶佔更大市場份額，提升未來財務表現及估值。
- 監管里程碑： 產品獲國家監管部門批准，證明公司研發及合規能力，增強投資者信心。
董事會及管理層動態
公告由董事會主席蔡東晨先生於2026年5月26日發出。現時董事會成員包括多位執行董事及獨立非執行董事，顯示公司具備穩健的治理及戰略領導力。
總結
蘭索拉唑腸溶膠囊獲批屬於公司重要里程碑，預料對公司股價及未來增長帶來積極影響。建議投資者密切留意產品商業化及市場推廣進展。
免責聲明： 以上內容僅供參考，並不構成任何投資建議。投資者應自行進行充分調查，並諮詢專業財務顧問後作出投資決定。
